Cetilistat

Drug Profile

Cetilistat

Alternative Names: ATL-962; AZM-119; Cametor; Oblean

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Alizyme
  • Developer Alizyme; Takeda
  • Class Benzoxazines; Obesity therapies; Small molecules
  • Mechanism of Action Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Obesity
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 20 Jun 2015 Launched for Obesity in Japan (PO)
  • 20 Jun 2015 No recent reports of development identified - Phase-II for Obesity in Europe and USA (PO)
  • 20 Jun 2015 No recent reports of development identified - Phase-II for Type-2 diabetes mellitus in USA and Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top